TheraRadar
← Back
Data updated: Jun 28, 2026

HANFORD GC

Generics

HANFORD GC is a generic drug manufacturer focused on Infectious Disease, Gastroenterology.

1993
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

HANFORD GC's Key Drugs

HANFORD GC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HANFORD GC's Recent FDA Approvals

New NDA/BLA approvals for HANFORD GC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HANFORD GC's Therapeutic Areas

HANFORD GC's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 50%
1 drugs
Gastroenterology 50%
1 drugs

HANFORD GC's Top Competitors

HANFORD GC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

HANFORD GC Pipeline Snapshot

Active clinical trials for HANFORD GC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling